A detailed history of Exane Derivatives transactions in Moderna, Inc. stock. As of the latest transaction made, Exane Derivatives holds 4,267 shares of MRNA stock, worth $214,587. This represents 0.39% of its overall portfolio holdings.

Number of Shares
4,267
Previous 3,917 8.94%
Holding current value
$214,587
Previous $674,000 9.64%
% of portfolio
0.39%
Previous 0.21%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 12, 2022

BUY
$117.13 - $176.59 $40,995 - $61,806
350 Added 8.94%
4,267 $609,000
Q1 2022

Apr 22, 2022

SELL
$126.46 - $235.05 $1,770 - $3,290
-14 Reduced 0.36%
3,917 $674,000
Q4 2021

Jan 28, 2022

BUY
$225.82 - $368.51 $356,118 - $581,140
1,577 Added 66.99%
3,931 $998,000
Q3 2021

Oct 26, 2021

SELL
$221.9 - $484.47 $30,844 - $67,341
-139 Reduced 5.58%
2,354 $905,000
Q2 2021

Jul 28, 2021

SELL
$129.91 - $234.98 $813,496 - $1.47 Million
-6,262 Reduced 71.52%
2,493 $585,000
Q1 2021

Apr 30, 2021

BUY
$109.18 - $185.98 $679,863 - $1.16 Million
6,227 Added 246.32%
8,755 $1.15 Million
Q4 2020

Jan 27, 2021

BUY
$65.74 - $169.86 $11,701 - $30,235
178 Added 7.57%
2,528 $264,000
Q2 2020

Jul 10, 2020

BUY
$29.67 - $80.0 $69,724 - $188,000
2,350 New
2,350 $150,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $19.7B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.